Proteus Mirabilis
Proteus Mirabilis
Proteus Mirabilis
net/publication/347464724
CITATIONS READS
0 846
4 authors, including:
Ahmed Aljanaby
University Of Kufa
63 PUBLICATIONS 443 CITATIONS
SEE PROFILE
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Ahmed Aljanaby on 03 January 2021.
ABSTRACT
A common cause of the urinary tract is Proteus mirabilis. This microorganism has many factors of virulence.
Proteus mirabilis may express adhesins, flagella, toxins, enzymes, quorum sensing, and factors for immune
avoidance. This pathogen is determined as an opportunistic pathogen responsible for many infections like
urinary tract infections (UTIs) and nosocomial infections in immunocompromised patients and who suffer from
various diseases.
Keywords: Swarming; UTIs; Virulence Factors; Immune System
2145| International Journal of Pharmaceutical Research | Jan - Mar 2021 | Vol 13 | Issue 1
Thualfakar Hayder Hasan et al / Proteus Mirabilis Virulence Factors: Review
2146| International Journal of Pharmaceutical Research | Jan - Mar 2021 | Vol 13 | Issue 1
Thualfakar Hayder Hasan et al / Proteus Mirabilis Virulence Factors: Review
2147| International Journal of Pharmaceutical Research | Jan - Mar 2021 | Vol 13 | Issue 1
Thualfakar Hayder Hasan et al / Proteus Mirabilis Virulence Factors: Review
11. Chahales, P., & Thanassi, D. G. (2017). Structure, Sys Rev Pharm 2020; 11(6): 817-823. DOI:
function, and assembly of adhesive organelles by 10.31838/srp.2020.6.118.
uropathogenic bacteria. Urinary Tract Infections: 23. Hasan, T. H. (2020a). Extended Spectrum Beta
Molecular Pathogenesis and Clinical Management, Lactamase E. Coli isolated from UTI Patients in
277-329. Najaf Province, Iraq. International Journal of
12. Dal Peraro, M., & Van Der Goot, F. G. (2016). Pharmaceutical Research,2020. 12.4.673-677.
Pore-forming toxins: ancient, but never really out 24. Hasan, T. H. (2020b). Extended Spectrum Beta-
of fashion. Nature reviews microbiology, 14(2), Lactamase Producing Klebsiella Pneumonia
77-92. Isolated from Patients with Urinary Tract
13. Debnath, I., Stringer, A. M., Smith, S. N., Bae, E., Infection in Al-Najaf Governorate – Iraq.
Mobley, H. L., Wade, J. T., & Pearson, M. M. International Journal of Advances in Science,
(2018). MrpJ directly regulates proteus mirabilis Engineering and Technology(IJASEAT),8(1),13-16.
virulence factors, including fimbriae and type VI 25. Hasan, T.H., Al-Harmoosh, R.A., Al-Khilkhali,
secretion, during urinary tract infection. Infection H.J.B.(2020). Identification of HIV virus in najaf
and immunity, 86(10). city, Iraq. International Journal of Research in
14. Ebringer, A., Rashid, T., Wilson, C., Ptaszynska, Pharmaceutical Sciences, 2020, 11(3), pp. 4866-
T., & Fielder, M. (2006). Ankylosing Spondylitis, 4871.
HLA-B27 and Klebsiella-an overview: proposal 26. Hayder, T., & Aljanaby, A. A. J. J. (2019a).
for early diagnosis and treatment. Current Antibiotics susceptibility patterns of Citrobacter
Rheumatology Reviews, 2(1), 55-68. freundii isolated from pa-tients with urinary tract
15. Engel, P., Brandt, K. K., Rasmussen, L. H., infection in Al-Najaf governorate– Iraq.
Ovesen, R. G., & Sørensen, J. (2007). Microbial International Journal of Research in
degradation and impact of Bracken toxin Pharmaceutical Sciences, 10(2), 1481-1488
ptaquiloside on microbial communities in 27. Hayder, T., & Aljanaby, A. A. J.(2019b).
soil. Chemosphere, 67(1), 202-209. Genotypic Characterization of Antimicrobial
16. Etxaniz, A., González‐Bullón, D., Martín, C., Resistance-Associated Genes in Citrobacter
Alonso, M. T., & Ostolaza, H. (2020). Irreversible Freundii Isolated from Patients with Urinary
versus repairable membrane poration: Tract Infection in Al-Najaf GovernorateIraq.
differences in permeabilization elicited by OnLine Journal of Biological Sciences, 19(2),
Bordetella Adenylate Cyclase Toxin and its 132–145.
hemolysin domain in macrophages. The FEBS 28. Hertle, R. (2005). The family of Serratia type
Journal, 287(9), 1798-1815. pore forming toxins. Current Protein and
17. Fattorini, C., Lopez-Beltran, A., & Raspollini, M. Peptide Science, 6(4), 313-325.
R. (2020). Urothelial Carcinoma, Sarcomatoid 29. Hickling, D. R., Sun, T. T., & Wu, X. R. (2017).
Type. Uropathology, 491-493. Anatomy and physiology of the urinary tract:
18. Flannery, E. L., Mody, L., & Mobley, H. L. (2009). relation to host defense and microbial
Identification of a modular pathogenicity island infection. Urinary Tract Infections: Molecular
that is widespread among urease-producing Pathogenesis and Clinical Management, 1-25.
uropathogens and shares features with a diverse 30. Jacobsen, S. M., Stickler, D. J., Mobley, H. L. T., &
group of mobile elements. Infection and Shirtliff, M. E. (2008). Complicated catheter-
immunity, 77(11), 4887-4894. associated urinary tract infections due to
19. Fusco, A., Coretti, L., Savio, V., Buommino, E., Escherichia coli and Proteus mirabilis. Clinical
Lembo, F., & Donnarumma, G. (2017). Biofilm microbiology reviews, 21(1), 26-59.
formation and immunomodulatory activity of 31. Jiang, W., Ubhayasekera, W., Pearson, M. M., &
Proteus mirabilis clinically isolated Knight, S. D. (2018). Structures of two fimbrial
strains. International journal of molecular adhesins, AtfE and UcaD, from the uropathogen
sciences, 18(2), 414. Proteus mirabilis. Acta Crystallographica Section
20. Gupta, A., Mumtaz, S., Li, C. H., Hussain, I., & D: Structural Biology, 74(11), 1053-1062.
Rotello, V. M. (2019). Combatting antibiotic- 32. Kadhum, H. A., & Hasan, T. H. (2019). The Study
resistant bacteria using nanomaterials. Chemical of Bacillus Subtils Antimicrobial Activity on Some
Society Reviews, 48(2), 415-427. of the Pathological Isolates. International Journal
21. Habibi, M., Karam, M. R. A., Shokrgozar, M. A., of Drug Delivery Technology 2019; 9(2); 193-
Oloomi, M., Jafari, A., & Bouzari, S. (2015). 196. https://doi.org/10.25258/ijddt.9.2.12.
Intranasal immunization with fusion protein 33. Konieczna, I., Zarnowiec, P., Kwinkowski, M.,
MrpH· FimH and MPL adjuvant confers Kolesinska, B., Fraczyk, J., Kaminski, Z., & Kaca,
protection against urinary tract infections caused W. (2012). Bacterial urease and its role in long-
by uropathogenic Escherichia coli and Proteus lasting human diseases. Current Protein and
mirabilis. Molecular immunology, 64(2), 285-294. Peptide Science, 13(8), 789-806.
22. Hasan, T. H. & Al-Harmoosh, R. A. (2020). 34. Kotian, H. S., Abdulla, A. Z., Hithysini, K. N.,
Mechanisms of Antibiotics Resistance in Bacteria. Harkar, S., Joge, S., Mishra, A., ... & Varma, M. M.
2148| International Journal of Pharmaceutical Research | Jan - Mar 2021 | Vol 13 | Issue 1
Thualfakar Hayder Hasan et al / Proteus Mirabilis Virulence Factors: Review
(2020). Active modulation of surfactant-driven 46. Rutherford, J. C. (2014). The emerging role of
flow instabilities by swarming bacteria. Physical urease as a general microbial virulence
Review E, 101(1), 012407. factor. PLoS Pathog, 10(5), e1004062.
35. Kuan, L., Schaffer, J. N., Zouzias, C. D., & 47. Sarshar, M., Behzadi, P., Ambrosi, C., Zagaglia,
Pearson, M. M. (2014). Characterization of 17 C., Palamara, A. T., & Scribano, D. (2020). FimH
chaperone-usher fimbriae encoded by Proteus and Anti-Adhesive Therapeutics: A Disarming
mirabilis reveals strong conservation. Journal of Strategy Against Uropathogens. Antibiotics, 9(7),
medical microbiology, 63(Pt 7), 911. 397.
36. Liu, M. C., Kuo, K. T., Chien, H. F., Tsai, Y. L., & 48. Schaffer, J. N., & Pearson, M. M. (2017). Proteus
Liaw, S. J. (2015). New aspects of RpoE in mirabilis and urinary tract infections. Urinary
uropathogenic Proteus mirabilis. Infection and Tract Infections: Molecular Pathogenesis and
immunity, 83(3), 966-977. Clinical Management, 383-433.
37. Los, F. C., Randis, T. M., Aroian, R. V., & Ratner, 49. Schneider, R., Lockatell, C. V., Johnson, D., &
A. J. (2013). Role of pore-forming toxins in Belas, R. (2002). Detection and mutation of a
bacterial infectious diseases. Microbiology and luxS-encoded autoinducer in Proteus
Molecular Biology Reviews, 77(2), 173-207. mirabilisThe GenBank accession number for the
38. Majeed, H. T., and Aljanaby, A. A. J. (2019). sequence reported in this paper is
Antibiotic Susceptibility Patterns and Prevalence AY044337. Microbiology, 148(3), 773-782.
of Some Extended Spectrum Beta-Lactamases 50. Simms, A. N., & Mobley, H. L. (2008). Multiple
Genes in GramNegative Bacteria Isolated from genes repress motility in uropathogenic
Patients Infected with Urinary Tract Infections in Escherichia coli constitutively expressing type 1
Al-Najaf City, Iraq. Avicenna journal of medical fimbriae. Journal of bacteriology, 190(10), 3747-
biotechnology, 11(2), 192. 3756.
39. Norsworthy, A. N., & Pearson, M. M. (2017). 51. Stankowska, D., Czerwonka, G., Rozalska, S.,
From catheter to kidney stone: the Grosicka, M., Dziadek, J., & Kaca, W. (2012).
uropathogenic lifestyle of Proteus Influence of quorum sensing signal molecules on
mirabilis. Trends in microbiology, 25(4), 304-315. biofilm formation in Proteus mirabilis O18. Folia
40. Majeed, H.T., Hasan, T.H., Aljanaby, A.A.J.(2020). microbiologica, 57(1), 53-60.
Epidemiological study in women infected with 52. Sun, J., Deering, R. W., Peng, Z., Najia, L., Khoo,
toxoplasma gondii, rubella virus, and cytomegalo C., Cohen, P. S., ... & Rowley, D. C. (2019).
virus in Al-Najaf Governorate-Iraq. International Pectic Oligosaccharides from Cranberry Prevent
Journal of Pharmaceutical Research, 2020, 12, pp. Quiescence and Persistence in the
1442-1447 Uropathogenic Escherichia coli
41. Ostolaza, H., González-Bullón, D., Uribe, K. B., CFT073. Scientific reports, 9(1), 1-9.
Martín, C., Amuategi, J., & Fernandez-Martínez, 53. Tsai, Y. L., Chien, H. F., Huang, K. T., Lin, W. Y.,
X. (2019). Membrane Permeabilization by Pore- & Liaw, S. J. (2017). cAMP receptor protein
Forming RTX Toxins: What Kind of Lesions Do regulates mouse colonization, motility, fimbria-
These Toxins Form?. Toxins, 11(6), 354. mediated adhesion, and stress tolerance in
42. Qiao, G. G., O'Brien-Simpson, N. M., Lam, S. J., uropathogenic Proteus mirabilis. Scientific
& Reynolds, E. C. (2019). U.S. Patent Application reports, 7(1), 1-14.
No. 16/343,556. 54. Wang, W. B., Lai, H. C., Hsueh, P. R., Chiou, R.
43. Ranjbar-Omid, M., Arzanlou, M., Amani, M., Y. Y., Lin, S. B., & Liaw, S. J. (2006). Inhibition of
Shokri Al-Hashem, S. K., Amir Mozafari, N., & swarming and virulence factor expression in
Peeri Doghaheh, H. (2015). Allicin from garlic Proteus mirabilis by resveratrol. Journal of
inhibits the biofilm formation and urease activity medical microbiology, 55(10), 1313-1321.
of Proteus mirabilis in vitro. FEMS microbiology 55. Younis, K. M., Usup, G., & Ahmad, A. (2016).
letters, 362(9), fnv049. Secondary metabolites produced by marine
44. Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., streptomyces as antibiofilm and quorum-sensing
Mehrad, M., Monte, N. M., ... & Hirsch, M. S. inhibitor of uropathogen Proteus
(2010). High-grade fimbrial-ovarian carcinomas mirabilis. Environmental Science and Pollution
are unified by altered p53, PTEN and PAX2 Research, 23(5), 4756-4767.
expression. Modern Pathology, 23(10), 1316- 56. Zhang, Y., Yang, S., Dai, X., Liu, L., Jiang, X.,
1324. Shao, M., ... & Zhu, R. (2015). Protective
45. Rózalski, A., Sidorczyk, Z., & Koteł ko, K. R. Y. immunity induced by the vaccination of
S. T. Y. N. A. (1997). Potential virulence factors recombinant Proteus mirabilis OmpA expressed
of Proteus bacilli. Microbiology and Molecular in Pichia pastoris. Protein expression and
Biology Reviews, 61(1), 65-89. purification, 105, 33-38.
2149| International Journal of Pharmaceutical Research | Jan - Mar 2021 | Vol 13 | Issue 1